ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.1687C>T (p.Arg563Ter) (rs587778618)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132169 SCV000187247 pathogenic Hereditary cancer-predisposing syndrome 2017-04-18 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Color RCV000132169 SCV000686154 pathogenic Hereditary cancer-predisposing syndrome 2017-02-02 criteria provided, single submitter clinical testing
GeneDx RCV000222921 SCV000279143 pathogenic not provided 2017-07-06 criteria provided, single submitter clinical testing This variant is denoted PMS2 c.1687C>T at the cDNA level and p.Arg563Ter (R563X) at the protein level. The substitution creates a nonsense variant, which changes an Arginine to a premature stop codon (CGA>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been reported in the compound heterozygous state, with a PMS2 multi-exonic deletion, in an individual with childhood-onset rectal cancer, caf?-au-lait spots, and immunohistochemistry demonstrating an absence of PMS2 protein in the rectal tumor as well as the normal mucosa, consistent with constitutional mismatch repair deficiency (CMMR-D) (Vaughn 2010). PMS2 Arg536Ter has also been reported in an individual with a pediatric brain tumor and NF1 phenotype, suspected for CMMR-D but the second variant was not established, and in the homozygous state in a pediatric patient with AML and osteosarcoma (Vasovcak 2012, Ortiz 2016). We consider this variant to be pathogenic.
ITMI RCV000121846 SCV000086046 not provided not specified 2013-09-19 no assertion provided reference population
Invitae RCV000530464 SCV000625550 pathogenic Hereditary nonpolyposis colon cancer 2018-12-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg563*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs587778618, ExAC 0.02%). This variant has been observed in individuals affected with colorectal cancer, and in one of the cases, the individual was also affected with breast cancer (PMID: 25856668). In addition, this variant has been observed as homozygous or compound heterozygous in individuals with phenotypes consistent with autosomal recessive constitutional mismatch repair deficiency (CMMR-D) syndrome (PMID: 20205264, 22608206). ClinVar contains an entry for this variant (Variation ID: 135067). Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). For these reasons, this variant has been classified as Pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000222921 SCV000888400 pathogenic not provided 2016-08-12 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.